Brazil
VYROBIO is a biotechnology startup based in Brazil that aims to revolutionize the treatment of malignant central nervous system (CNS) tumors. Founded in 2021, the company is focused on developing next-generation viral immunotherapies for aggressive, fast-growing forms of CNS tumors, both pediatric and adult. Their pioneering approach involves the utilization of oncolytic viruses (OVs) based on the properties of the Zika virus.
The latest milestone for VYROBIO was the successful securing of a $1.50M Seed Round investment from Vesper Ventures SA on 19 February 2022. This funding is expected to drive the further advancement of their innovative immunotherapy solutions.
Overall, VYROBIO presents an intriguing proposition in the biotechnology space, leveraging cutting-edge virology research to address a critical medical need. With their pioneering spirit and the backing of Vesper Ventures SA, VYROBIO is poised to make significant strides in the development of oncolytic immunotherapies for CNS tumors.
